BioDiem brings a clear commercial focus to the pharmaceutical development business. We aim to distinguish a select number of viable potential products that have advanced data on efficacy and safety and take them cost effectively to market.

Commercialising Medical Research for the West

BioDiem has acquired its initial products from leading Russian medical research institutes. This alliance has provided BioDiem with access to research projects with advanced data, in three cases with clinical studies showing promising results.

To effectively manage development costs, BioDiem out-sources its research and development requirements to appropriate institutional centres of excellence and contract research organisations in Australia and overseas.

Income Goals

BioDiem intends to out-license its products at appropriate stages to international pharmaceutical companies, to take its products through late stage clinical studies and assessment by regulatory authorities, in order to get market approval in Western markets. It is intended that these out-licensing arrangements would provide income to BioDiem through milestone payments during development and through royalties on sales after market approval.